Physician profile
Elizabeth Machen
NPI 1790226074
$4,157.00
in general payments reported to CMS, 2019-2025
24 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $896 · 2023: $875 · 2024: $1,079 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.47 | 2021-2025 | |
| Genzyme Corporation | $330.98 | 2022-2025 | |
| Lilly USA, LLC | $291.89 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $265.71 | 2021-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $229.16 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $170.17 | 2022-2024 | |
| Arcutis Biotherapeutics, INC. | $154.43 | 2023-2025 | Zoryve |
| Incyte Corporation | $151.47 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $137.60 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $124.04 | 2023-2025 | Sotyktu |
| Ucb, INC. | $98.43 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $96.35 | 2024-2025 | |
| Amgen INC. | $74.67 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $68.88 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.73 | 2023-2025 | Spevigo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $45.48 | 2023 | Apexicon E |
| Mallinckrodt Hospital Products INC. | $38.22 | 2024-2025 | Acthar |
| Journey Medical Corporation | $34.00 | 2022-2025 | |
| Genentech USA, INC. | $31.08 | 2022 | |
| Almirall LLC | $29.93 | 2023 | Seysara |
| Allergan, INC. | $29.63 | 2022 | |
| Sanofi Pasteur INC. | $18.55 | 2024 | |
| Botanix Sb INC | $14.29 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Machen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.